不同年龄和血清HBV DNA水平慢性乙型肝炎患者肝组织病理学变化*

doi:10.3969/j.issn.1672-5069.2018.02.030

Abstract

Xiao Guibao. Pathological characteristics of liver tissues in chronic hepatitis B patients with different ages and serum HBV DNA loads[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 277-278.

[1] Thio CL,Guo N,Xie C,et al.Global elimination of mother-to-child transmission of hepatitis B:revisiting the current strategy. Lancet Infect Dis,2015,15(8):981-985.
[2] Kose S,Tatar B,Gül S,Pala E.The effect of long-term entecavir therapy on liver histopathology in patients with chronic viral hepatitis B.Acta Clin Belg,2016,71(4):244-249.
[3] Li N,Xu JH,Yu M,et al.Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy. World J Gastroenterol,2015,21(43):12421-12429.
[4] Toy M,Salomon JA,Jiang H,et al.Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai,China. Hepatology 2014,60(1):46-55.
[5] 杨秀珍,耿爱文,肖丽,等. 慢性乙型肝炎合并脂肪肝临床与肝组织病理学分析. 实用肝脏病杂志,2017,20(1):101-102.
[6] 杨丹球. 87例慢性乙型肝炎肝穿刺活检临床病理分析.中华全科医学,2010,8(4):419-420.
[7] Chang TT,Liaw YF,Wu SS,et al.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.Hepatology,2010,52(3):886-893.
[8] 霍雪平,谢琴秀,江晓平,等. 486例慢性乙型肝炎患者肝组织病理学变化与肝功能指标的相关性研究. 实用肝脏病杂志,2015,18(4):360-363.
[9] Gish RG,Chang TT,Lai CL,et al.Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir. Antivir Ther,2013,18(5):691-698.
[10] Liao B,Wang Z,Lin S,et al.Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent normal ALT. PLoS One,2013,8(10):e78672.
[11] Chao DT,Lin JK,Ayoub WS,et al.Systematic review with meta-analysis:the proportion of chronic hepatitis B patients with normal alanine transaminase≤40IU/L and significant hepatic fibrosis. Aliment Pharmacol Ther,2014,39(4):349-358.

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[3]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[4]	Wang Daowei, Fang Jian, Fan Ling.. Implication of serum IL-21 and chemokine levels in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2019, 22(6): 844-847.
[5]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[6]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[7]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.
[8]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[9]	Wang Baodan, Li Meng, Gao Yu. Predictive factors of response to interferon-α antiviral therapy in children with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 345-348.
[10]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[11]	Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.
[12]	Wang Yaofeng.. Efficacy and safety of tenofovir in the treatment of patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 847-850.
[13]	Huang Chunming, Yang Zhan, Nie Yuqiang, et al.. Prediction of liver fibrosis by gamma-glutamyl-transpeptidase-to-platelet ratio in patients with chronic hepatitis B viral infection with normal serum transaminase levels [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 859-862.
[14]	Baoyan, Wang Yun, Xiang Xiaogang, et al.. Prognosis of patients with hepatocellular carcinoma and underlying hepatitis B An [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 924-927.
[15]	Zheng Zhenchuan, Xu Xihai.. Pathological and clinical features and factors affecting significant liver fibrosis in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 713-716.

Pathological characteristics of liver tissues in chronic hepatitis B patients with different ages and serum HBV DNA loads

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments